ÂÜÀòÂÒÂ×

Erika Geimonen serves as Vice President, Business Development for Amring Pharmaceuticals. She is responsible for analyzing the market landscape to identify opportunities in product licensing, partnering and acquisitions that will help Amring Pharmaceuticals reach its strategic objectives. She evaluates the company’s business development opportunities, including M&A, in-licensing, divestment, alliances and out-licensing. She also leads the due diligence team that oversees all company acquisitions.

Dr. Geimonen has more than 23 years of experience in business development and research. Before joining Amring Pharmaceuticals, she was the Chief Operating Officer and Vice President, Business Development for Dynamis Therapeutics. In that position, she was responsible for all business development activities, managing operations, and raising capital for the company. Previously, Dr. Geimonen held business development positions at XBiotech, Luitpold Pharmaceuticals and Schering-Plough. Earlier in her career Dr. Geimonen held a series of research roles.

Dr. Geimonen co-chairs the Philadelphia chapter of Licensing Executives Society. She earned her M.S. in Biology and Ph.D. in Biology and Biochemistry from Moscow State University in Russia and an M.S. in Management and Policy from the College of Business at the State University of New York at Stony Brook.